All events are free. Other topics covered include the impact of new and emerging global infectious diseases such as coronavirus; innovative new methods for detecting ovarian cancer; the promises and pitfalls of gene editing; the rise of antibiotic-resistant superbugs; the worlds second HIV cure; and using stem cells to regenerate damaged tissues.
Using state-of-the-art technology, researchers are now able to grow organoids miniature versions of organs. In Mini-organs in a dish: how organoids are revolutionising research (12 March), Dr Emma Rawlins, The Gurdon Institute, explains how organoids are grown and discusses why this new technology is so important for biomedical research.
Dr Rawlins said: Scientists have been growing animal and human cells in the laboratory for more than 60 years. While these lab-grown cells are a powerful research tool, providing the basis for important developments in modern medicine, including some cancer drugs, anti-HIV therapies and vaccines, they are grown in very artificial conditions and therefore dont resemble any cells in our bodies. Ten years ago, Professor Hans Clevers and colleagues in the Netherlands invented a more complex cell culture system in which mini-organs, or organoids, could be grown. This discovery has led to a worldwide revolution in cell growth.
Scientists in Cambridge are at the forefront of this research, and mini-guts, livers, lungs, kidneys, placentas and even brains are growing in labs all over the city. This ability to study cells in a more natural setting provides many new and interesting research opportunities. Organoid technology has already been used to study human embryonic development, to test personalised treatments for cystic fibrosis and to replace some of the animals used in drug testing. Scientists are now exploring its potential for growing replacement organs, repairing damaged genes and providing personalised treatments for other diseases.
Researchers are also exploring whether they can print biomaterials to repair organs amongst other healthcare benefits. In 3D printing for healthcare (14 March), Dr Yan Yan Shery Huang, Department of Engineering, gives an overview on how 3D printing technologies could transform the way implants are produced, drugs are screened or perhaps even how damaged organs are repaired.
3D printing is already making impacts on patients needing artificial limbs, where the plastic-based prosthesis can be made 'personalised' to shapes and sizes, with relatively low-cost and short production time, Dr Huang said. For 3D printed personalised implants it is more technologically demanding; although, non-biological material-based implants are making their ways to the market and patients, such as 3D printed dental implants and implants for bone structural reconstruction.
Research is now focused on overcoming challenges in using 3D printing for biological materials and even living materials like cells. Applications are focused on two main streams: bioprinting for tissue and organ function replacements, including printing a scaffold for a heart, a human ear, and a blood vessel-permeated-bioreactor; and bioprinting for drug testing pseudo-models of different levels of complexities, from brain to muscles have already been created. Research is continuing, with the aim to reduce and replace animal studies and to improve the predictive power of the models.
Hardening of the arteries is a widespread condition that is a major cause of cardiovascular disease, including heart attacks and stroke. Stroke is also linked to vascular dementia and is one of the nations major causes of adult disability there is a stroke every five minutes in the UK and costs the economy 26b per annum. This figure is expected to triple by 2035. Despite the huge impact that hardened arteries have for human health, there are still no cures. In More than a blocked pipe: the hardening of arteries and their role in stroke and heart attacks (18 March), Dr Nick Evans, Department of Medicine, and Professor Melinda Duer, Department of Chemistry, discuss their combined efforts to find better diagnoses and treatments. They reveal new research and findings on how hardened arteries can be diagnosed more precisely through PET (positron emission tomography), which is proving to be an excellent way to assess carotid calcification in patients and could lead to potential new drug treatment.
Speaking ahead of the event, Professor Duer said: To stop artery calcification, we need to stop the mineral from forming in the artery wall in the first place. We have very recently discovered that a molecule known as poly(ADP ribose), produced by cells in the artery wall that are stressed from fatty deposits around them, is responsible for initiating the formation of the mineral deposits. poly(ADP ribose) gathers calcium and sticks it to the collagen and other molecules in the artery wall, so concentrating the calcium into specific spots in the artery wall which then allows mineral to form. The exciting treatment possibility is to stop stressed cells from making poly(ADP ribose) if it works, it will be the first drug treatment for vascular calcification.
Dr Evans added: Our newly presented research also shows how we can identify the microcalcification in patients using PET and how it gives us an understanding of the different processes causing atherosclerotic plaques (the hardening of arteries) to become damaged and trigger clots to form that cause a stroke.
Scientists and researchers at the forefront of tackling ovarian cancer are also making breakthroughs. In Tackling ovarian cancer: turning the tide on one of the toughest cancers (19 March), Cancer Research UK Cambridge Institute (CRUK CI), the Department of Radiology and AstraZeneca discuss how they are rapidly turning the tide on ovarian cancer using innovative new detection methods and through new treatments, such as Olaparib which was made available in the UK in December 2019.
The new detection methods currently being researched by CRUK CI include liquid biopsy, a process that uses advanced genomic technologies to extract cancer tumour DNA fragments from patients blood plasma. The process offers earlier detection and is far less invasive for patients. Another method is virtual biopsy using state-of-the-art imaging techniques, which is also being researched by the Department of Radiology, University of Cambridge.
The final day of the Festival, Sunday 22nd March, is dedicated to health with over 50 events hosted across Cambridge Biomedical Campus (CBC). Events include Gene editing: rewriting the future! Dr Alasdair Russell, CRUK CI, talks about the CRISPR genome editing revolution, its promise and its pitfalls. In The story of HIV Public Health England and partner organisations discuss the history of HIV in England and show how we have come so far in the diagnosis, treatment and care of people living with the illness. During Open science at the Jeffrey Cheah biomedical centre, visitors can learn more about the new kids on the block on the CBC and chat with scientists about stem cells, infectious diseases, cancer and new therapies. Tours of Royal Papworth Hospital offer a look inside one of the worlds leading heart and lung hospitals and a chance to meet the outstanding teams involved in delivering patient care.
Further related health-related events:
Bookings open on Monday 10 February at 11am.
The full programme can downloaded via Cambridge Science Festival>>>
Image: Talking science with the Department of Materials Science and MetallurgyCredit: Domininkas Zalys
Keep up to date with the Festival on social media via Facebook and Twitter #CamSciFest and Instagram.
This years Festival sponsors and partners are Cambridge University Press, AstraZeneca, Illumina, TTP Group, Anglia Ruskin University, Cambridge Epigenetix, Cambridge Science Centre, Cambridge Junction, IET, Hills Road 6th Form College, British Science Week, Cambridge University Health Partners, Cambridge Academy for Science and Technology, and Walters Kundert Charitable Trust. Media Partners: BBC Radio Cambridgeshire and Cambridge Independent.
View original post here:
Cambridge Science Festival showcases new research at the forefront of healthcare and medicine - Cambridge Network
- Hannah just thought she was being clumsy, but her bruises were a sign she needed to see her doctor - Daily Mail - October 27th, 2023
- Brent Rutemiller's Cancer In Early Remission After 42 Weeks of Chemotherapy and Stem Cell Transplant - Swimming World Magazine - May 20th, 2022
- Other Notable Health Studies & Research From May 17, 2022 - Study Finds - May 20th, 2022
- Clinton County Relay For Life holds annual event in Riverview Park - Lock Haven Express - May 20th, 2022
- Illinois Is Being Invaded By Worms That Jump A Foot In The Air - 1440wrok.com - May 20th, 2022
- Moderna, J&J COVID Booster Shots Near Authorization. Here's What to Know - NBC Chicago - October 26th, 2021
- GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF- R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research -... - October 26th, 2021
- Merck Provides Update on KEYTRUDA (pembrolizumab) Indication in Third-Line Gastric Cancer in the US - Business Wire - July 6th, 2021
- Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene - GlobeNewswire - July 6th, 2021
- New global guidelines for stem cell research aim to drive discussions, not lay down the law - The Conversation AU - May 27th, 2021
- Merck (MRK) Granted Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination with Chemotherapy - StreetInsider.com - May 27th, 2021
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal... - May 27th, 2021
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press - May 27th, 2021
- OPDIVO (nivolumab) in Combination with CABOMETYX (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for... - February 14th, 2021
- AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience - Business Wire - February 14th, 2021
- Opdivo in Combination with Cabometyx Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced RCC -... - February 14th, 2021
- Astellas and Seagen Announce Presentation of Results from PADCEV (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced... - February 14th, 2021
- [Full text] Loganin Attenuates Septic Acute Renal Injury with the Participation of | DDDT - Dove Medical Press - February 14th, 2021
- [Full text] Encephalopathy Induced by Preventive Administration of Acyclovir in a | IJGM - Dove Medical Press - February 14th, 2021
- Joint inflammation: Causes, treatment, and symptoms - Medical News Today - February 14th, 2021
- Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz Therapeutic Activity - PRNewswire - February 3rd, 2021
- How Coronavirus Damages Lung Cells Within Mere Hours And What Drugs Could Halt COVID-19 Infection - SciTechDaily - February 3rd, 2021
- Mini kidneys bioprinted in the lab - Lab + Life Scientist - December 4th, 2020
- Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - BioSpace - December 4th, 2020
- News briefing: Four biotechs announce IPO terms, setting the pace to round out a busy year; FDA sets PDUFA date for Kadmon's graft-versus-host drug -... - December 4th, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - Philippine Canadian... - December 4th, 2020
- Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic... - November 11th, 2020
- KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall... - November 11th, 2020
- Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020 - Investing News Network - November 11th, 2020
- The great reset: new danger on the horizon - Amandala - November 11th, 2020
- Teladoc Is A Strong Buy: A Radical Healthcare Change Will Come - Seeking Alpha - November 11th, 2020
- COVID Drug Given to Trump Developed From Aborted Fetus Cells - Quint Fit - October 10th, 2020
- Lars Jaeger: The Future is Veggie, With 3D Printing - finews.asia - October 10th, 2020
- Laid off from ImmunoGen, an ex-Genzyme and Shire exec heads to an ARCH upstart - Endpoints News - October 10th, 2020
- 5 Deadly Pre-existing Conditions You Could Have Due To COVID-19 - Brumpost - Brumpost - October 10th, 2020
- The Crypto Daily Movers and Shakers October 10th, 2020 - Sports Grind Entertainment - October 10th, 2020
- Coronavirus Tracker: Bexar Co. cases surpass 59,000; Texas hospitalizations trending in the wrong direction - KENS5.com - October 10th, 2020
- Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million - Business Wire - September 24th, 2020
- Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations - BioSpace - September 15th, 2020
- Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis - Business Wire - September 15th, 2020
- Braunstein Reflects on the Rise of Quadruplet Therapies in Multiple Myeloma - OncLive - September 9th, 2020
- Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients - GlobeNewswire - September 9th, 2020
- ASX Biotechs Surfing The Covid Story - FN Arena News - August 16th, 2020
- Merck and Eisai Receive Complete Response Letter for KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) Combination as First-Line Treatment for... - July 10th, 2020
- FDA Approves Talaris Therapeutics' IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma - Business... - July 10th, 2020
- Coronavirus PPP Loans In Livingston: Where The Money Went - Livingston, NJ Patch - July 9th, 2020
- Stem Cell Therapy For Kidney Failure. Learn More Now ... - July 7th, 2020
- Anemia in chronic kidney disease - kidneyfund.org - July 7th, 2020
- Dr Borehams Crucible: Mesoblast within months of 3 major trial results, key regulatory decision - Stockhead - July 7th, 2020
- FDA Approves Merck's KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer -... - June 30th, 2020
- R3 International Offering Stem Cell Therapy Program for Anti Aging in Mexico - PR Web - June 30th, 2020
- Vitro Bio-Pharma 2nd Quarter Ended April 30th 2020 Financial Results of Operations and Shareholder Letter - Stockhouse - June 30th, 2020
- FDA Approves Merck's KEYTRUDA (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that... - June 25th, 2020
- Simcha Therapeutics Launches to Engineer Therapeutic Cytokines to Unlock the Full Potential of the Immune System - Business Wire - June 25th, 2020
- First American to Receive Placental Cell Treatment For COVID-19 is an Acclaimed Broadway Scenic Designer - Science Times - May 27th, 2020
- Scientists generate millions of mature human cells, far more than have ever been produced - UB News Center - May 20th, 2020
- Heres The Reason Why Scientists Are Growing Human Cells In Mouse Embryo - Medical Daily - May 20th, 2020
- Cell therapies trial planned for COVID-19 - Mirage News - May 5th, 2020
- New Study Finds That Wearing Contact Lenses Doesn't Increase Risk of COVID-19 Infection - HealthDay Coronavirus Liveblog - April 26th, 2020
- Israeli COVID-19 treatment with 100% survival rate tested on US patient - The Jerusalem Post - April 15th, 2020
- Stem Cells and Chronic Kidney Disease | Mayo Clinic Center ... - April 11th, 2020
- Kidney Failure | Stem Cell Treatment in Tijuana Mexico - April 11th, 2020
- MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTHS NATIONAL HEART, LUNG AND... - April 11th, 2020
- Merck Receives Priority Review from FDA for Second Application for KEYTRUDA (pembrolizumab) Based on Biomarker, Regardless of Tumor Type - Benzinga - April 11th, 2020
- A coronavirus vaccine is being developed in record time. But dont expect that technology to speed up flu vaccines yet. - Columbia Daily Herald - April 7th, 2020
- Researchers test drug that stops early stages of COVID-19 - Open Access Government - April 7th, 2020
- Can cell-based therapy be helpful in tackling coronavirus? - YourStory - March 25th, 2020
- Made-in-space organs could soon be reality - ETHealthworld.com - March 13th, 2020
- What Is the Coronavirus? - WIRED - March 6th, 2020
- 34 years with a new heart and counting - MDJOnline.com - February 25th, 2020
- Coronavirus: Doctors try 3,000-year-old Traditional Chinese Medicine (TCM) to treat the virus - Times of India - February 20th, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for... - February 14th, 2020
- Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy... - February 14th, 2020
- Omeros: 2 Major Catalysts On The Horizon - Seeking Alpha - February 10th, 2020
- Anemia: Causes, symptoms and treatment - Livescience.com - February 8th, 2020
- 4 Crazy but Effective Ways to Save More Money This Year - Nasdaq - February 4th, 2020
- BAME lives to be saved as new organ donation law rolls out - Keep the Faith - January 15th, 2020
- HIV drug resistance an emerging threat, expert warns - DAWN.com - January 10th, 2020
- A Lasting Legacy: DuPont, C8 Contamination and the Community Left to Grapple With the Consequences - alleghenyfront.org - January 10th, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as... - January 6th, 2020